Effects of long-term intake of edible oils on hypertension and myocardial and aortic remodelling in spontaneously hypertensive rats

Journal of Hypertension

Volumn 22, Issue 5, 2004, Pages 921-929

  Aguila, Marcia Barbosa ^a,b   Sa Silva, Suzana P ^a   Pinheiro, Alessandra R ^a   Mandarim de Lacerda, Carlos Alberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

Aorta; Canola oil; Fish oil; Heart; Hypertension; Olive oil; Palm oil; Soybean oil; Stereology

Indexed keywords

CANOLA OIL; EDIBLE OIL; FISH OIL; OLIVE OIL; PALM OIL; SOYBEAN OIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; AORTA WALL; ARTERY RECONSTRUCTION; ARTICLE; BLOOD PRESSURE; CONNECTIVE TISSUE; CONTROLLED STUDY; HEART MUSCLE; HEART MUSCLE CELL; HYPERTENSION; INTESTINE; LONG TERM EXPOSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAPESEED; RAT; SMOOTH MUSCLE FIBER; STEREOLOGY; TUNICA MEDIA;

EID: 2542422863     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200405000-00013     Document Type: Article

References (49)

1. Engler MM, Engler MB. Dietary borage oil alters plasma, hepatic and vascular tissue fatty acid composition in spontaneously hypertensive rats. Prostaglandins Leukot Essent Fatty Acids 1998; 59:11-15.
2. Conlin PR, Chow D, Miller ER 3rd, Svetkey LP, Lin PH, Harsha DW, et al. The effect of dietary patterns on blood pressure control in hypertensive patients: results from the Dietary Approaches to Stop Hypertension (DASH) trial. Am J Hypertens 2000; 13:949-955.
3. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88:523-533.
4. Bexis S, Lungershausen YK, Mano MT, Howe PR, Kong JQ, Birkle DL, et al. Dietary fish oil administration retards blood pressure development and influences vascular properties in the spontaneously hypertensive rat (SHR) but not in the stroke prone-spontaneously hypertensive rat (SHR-SP). Blood Press 1994; 3:120-126.
5. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20:1493-1499.
6. Engler MB, Ma YH, Engler MM. Calcium-mediated mechanisms of eicosapentaenoic acid-induced relaxation in hypertensive rat aorta. Am J Hypertens 1999; 12:1225-1235.
7. O'Keefe JH Jr, Harris WS. From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000; 75:607-614.
8. Cattaneo L, De Gennaro Colonna V, Zoli M, Muller EE, Cocchi D. Hypothalamo-pituitary-IGF-1 axis in female rats made obese by over-feeding. Life Sci 1997; 61:881-889.
9. Baddeley AJ, Gundersen HJ, Cruz-Orive LM. Estimation of surface area from vertical sections. J Microsc 1986; 142:259-276.
10. Scherle W. A simple method for volumetry of organs in quantitative stereology. Mikroskopie 1970; 26:57-60.
11. Weibel E. Stereological methods. Practical methods for biological morphometry. London: Academic Press; 1979.
12. Wistar rat H. Historical data: hematological values, clinical chemistry values, urinary values, organ weights. http://www.m-b.dk: M&B A/S, 1995.
13. Mattfeldt T, Mall G, Gharehbaghi H, Moller P. Estimation of surface area and length with the orientator. J Microsc 1990; 159:301-317.
14. Mandarim-de-Lacerda CA. Stereological tools in biomedical research. An Acad Bras Cienc 2003; 75:469-486.
15. Zar JH. Biostatistical analysis. Upper Saddle River: Prentice-Hall; 1999.
16. Ferrara LA, Raimondi AS, d'Episcopo L, Guida L, Dello Russo A, Marotta T. Olive oil and reduced need for antihypertensive medications. Arch Intern Med 2000; 160:837-842.
17. Bonaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromso study. N Engl J Med 1990; 322:795-801.
18. Chu ZM, Yin K, Beilin LJ. Fish oil feeding selectively attenuates contractile responses to noradrenaline and electrical stimulation in the perfused mesenteric resistance vessels of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1992; 19:177-181.
19. Kim P, Shimokawa H, Vanhoutte PM. Dietary omega-3 fatty acids and endothelium-dependent responses in porcine cerebral arteries. Stroke 1992; 23:407-413.
20. McLennan PL, Dallimore JA. Dietary canola oil modifies myocardial fatty acids and inhibits cardiac arrhythmias in rats. J Nutr 1995; 125:1003-1009.
21. Abeywardena MY, Head RJ. Dietary polyunsaturated fatty acid and antioxidant modulation of vascular dysfunction in the spontaneously hypertensive rat. Prostaglandins Leukot Essent Fatty Acids 2001; 65:91-97.
22. Aguila MB, Mandarim-de-Lacerda CA. Heart and blood pressure adaptations in Wistar rats fed with different high-fat diets for 18 months. Nutrition 2003; 19:347-352.
23. Aguila MB, Mandarim-de-Lacerda CA. Blood pressure, ventricular volume and number of cardiomyocyte nuclei in rats fed for 12 months on diets differing in fat composition. Mech Ageing Dev 2001; 122:77-88.
24. Sugano M, Imaizumi K. Effect of palm oil on lipid and lipoprotein metabolism and eicosanoid production in rats. Am J Clin Nutr 1991; 53:1034S-1038S.
25. Ganafa AA, Socci RR, Eatman D, Silvestrov N, Abukhalaf IK, Bayorh MA. Effect of palm oil on oxidative stress-induced hypertension in Sprague-Dawley rats. Am J Hypertens 2002; 15:725-731.
26. Osim EE, Owu DU, Etta KM. Arterial pressure and lipid profile in rats following chronic ingestion of palm oil diets. Afr J Med Sci 1996; 25:335-340.
27. Charnock JS, Abeywardena MY, McLennan PL. Omega-3 and omega-6 PUFAs have different effects on the phospholipid fatty acid composition of rat myocardial muscle when added to a saturated fatty acid dietary supplement. Nutr Res 1991; 11:1013-1024.
28. Pereira LM, Mandarim-de-Lacerda CA. Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade. Pathol Res Pract 2000; 196:305-311.
29. Amann K, Tornig J, Buzello M, Kuhlmann A, Gross ML, Adamczak M, et al. Effect of antioxidant therapy with DL-alpha-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int 2002; 62:877-884.
30. McLennan P, Howe P, Abeywardena M, Muggli R, Raederstorff D, Mano M, et al. The cardiovascular protective role of docosahexaenoic acid. Eur J Pharmacol 1996; 300:83-89.
31. Carr A, Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic Biol Med 2000; 28:1806-1814.
32. Michel JB, Heudes D, Michel O, Poitevin P, Philippe M, Scalbert E, et al. Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries. Am J Physiol Regul Integr Comp Physiol 1994; 267:R124-R135.
33. Nakayama M, Fukuda N, Watanabe Y, Soma M, Hu WY, Kishioka H, et al. Low dose of eicosapentaenoic acid inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats through suppression of transforming growth factor-beta. J Hypertens 1999; 17:1421-1430.
34. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 2000; 36:851-855.
35. 2+ current. Hypertension 2000; 35:832-837.
36. Grimsgaard S, Bonaa KH, Jacobsen BK, Bjerve KS. Plasma saturated and linoleic fatty acids are independently associated with blood pressure. Hypertension 1999; 34:478-483.
37. Aguila MB, Mandarim-de-Lacerda CA. Aorta wall quantitative alterations due to different long-term high-fat diet in rats. Food Chem Toxicol 2003; 41:1391-1397.
38. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405:421-424.
39. Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 2003; 3:186-191.
40. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997; 11:779-791.
41. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
42. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
43. Lindi V, Schwab U, Louheranta A, Laakso M, Vessby B, Hermansen K, et al. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol Genet Metab 2003; 79:52-60.
44. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129:823-834.
45. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPAR-alpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384:39-43.
46. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50:2094-2099.
47. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143:998-1007.
48. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102:1296-1301.
49. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96:1723-1732.